CDSCO clears recombinant live attenuated dengue vaccine for ages 4 to 60 years
‘The approval has been granted after a comprehensive scientific evaluation of the vaccine’s quality, safety and efficacy,’ said the Union Health Ministry
360° Perspective Analysis
Deep-dive into Geography, Polity, Economy, History, Environment & Social dimensions — AI-powered, on-demand
Context
India has approved its first dengue vaccine, Qdenga, a live, attenuated tetravalent vaccine for individuals aged 4 to 60. The approval by the under the marks a significant step in complementing existing vector control measures under the .
UPSC Perspectives
Science & Technology
Understanding the science behind Qdenga is crucial for GS-3. The vaccine utilizes recombinant DNA technology, specifically engineering genes for serotype-specific surface proteins into a dengue virus type-2 backbone. This makes it a tetravalent vaccine, meaning it is designed to protect against all four serotypes of the dengue virus. Crucially, it is a live, attenuated vaccine, which means it uses a weakened form of the virus to stimulate an immune response without causing the disease itself. The use of Vero cells (a widely used lineage of cells used for culturing viruses) for production is standard practice in vaccine manufacturing. UPSC often tests knowledge of these vaccine technologies (e.g., mRNA vs. vector vs. live attenuated) and the specific nature of diseases like dengue (a viral infection transmitted by Aedes mosquitoes, with four distinct serotypes). This approval highlights India's growing capacity to integrate complex biotechnological advancements into public health solutions.
Governance
The regulatory pathway for vaccine approval in India falls squarely within GS-2 (Governance and Regulatory Bodies). The , functioning under the Directorate General of Health Services (Ministry of Health and Family Welfare), is the apex regulatory body for pharmaceuticals and medical devices. The approval of Qdenga was granted after a comprehensive evaluation of its quality, safety, and efficacy, as mandated by the and the . This process involves assessing data from global clinical trials, including a pivotal Phase III study in the Indian population, ensuring the vaccine is suitable for the local demographic. The fact that the vaccine also has prequalification and regulatory approval in 42 countries adds a layer of international validation. This highlights the importance of rigorous regulatory frameworks in ensuring public safety while facilitating access to life-saving medical innovations.
Social
From a public health perspective (GS-2), the introduction of a dengue vaccine is a game-changer. Dengue is a major public health challenge in India, placing a significant burden on the healthcare system and economy, primarily affecting urban and semi-urban populations during the monsoon season. Currently, the management of dengue relies heavily on vector control (managing mosquito populations), surveillance, and early diagnosis under the . The vaccine will serve as an essential complementary tool, potentially reducing the incidence and severity of the disease, thereby alleviating the strain on healthcare resources. This aligns with the broader goal of improving health outcomes and achieving universal health coverage. The strategic deployment of the vaccine, considering its efficacy across different age groups and regions, will be crucial for its overall success in mitigating the public health impact of dengue.